Lupin announced that it has entered into a license and supply agreement with Zentiva, k.s. for the commercialization of its biosimilar Certolizumab Pegol.

Lupin & Zentiva ink licensing and supply agreement for commercializing biosimilar Certolizumab Pegol: Our Bureau, Mumbai Wednesday, July 9, 2025, 16:20 Hrs [IST] Global Pharma maj ...

Amgen has transitioned into a mature, cash-generating pharma-biotech hybrid. Click here to find out why AMGN stock is a Buy.

Lupin's share price rose in trade today after the company announced a licensing and supply agreement with Zentiva, k.s., for ...

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the expansion of its capacity for ...

It is indicated for various diseases including heumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic ...

The US biosimilar market expands with new denosumab options, enhancing treatment for patients with osteoporosis and ...

President Trump threatened to impose up to 200% tariffs on pharmaceuticals imported into the U.S., but not immediately ...

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

JNJ which has outperformed the S&P 500 and other large-cap healthcare peers in H1-2025, now faces a crucial test with Q2 ...

JNJ's growth outlook, rising estimates, and strength in Innovative Medicine give it an edge over Pfizer in 2025.